We showed that MKI-1 exerted antitumor and radiosensitizer activities through PP2A-mediated c-Myc inhibition in breast cancer models, which suggested that MASTL targeting may be associated with the MASTL-PP2A-c-Myc axis in breast cancer. Here, MASTL is linked to breast carcinoma.